{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Safety+Study&page=14",
    "query": {
      "condition": "Safety Study",
      "page": 14
    },
    "page_size": 10
  },
  "pagination": {
    "page": 14,
    "page_size": 10,
    "total_count": 33591,
    "total_pages": 3360,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Safety+Study&page=15&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Safety+Study&page=13&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T07:17:24.281Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04338061",
      "title": "Study of Evobrutinib in Participants With RMS (evolutionRMS 2)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Relapsing Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Teriflunomide",
          "type": "DRUG"
        },
        {
          "name": "Evobrutinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 1166,
      "start_date": "2020-07-02",
      "completion_date": "2024-03-19",
      "has_results": true,
      "last_update_posted_date": "2025-03-21",
      "last_synced_at": "2026-11-19T07:17:24.281Z",
      "location_count": 38,
      "location_summary": "Cullman, Alabama • Scottsdale, Arizona • Tucson, Arizona + 34 more",
      "locations": [
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Hanford",
          "state": "California"
        },
        {
          "city": "West Hollywood",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04338061"
    },
    {
      "nct_id": "NCT00680342",
      "title": "Phase II Trial of Silymarin for Patients With Chronic Hepatitis C Who Have Failed Conventional Antiviral Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Silymarin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Center for Complementary and Integrative Health (NCCIH)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 154,
      "start_date": "2008-04",
      "completion_date": "2011-01",
      "has_results": false,
      "last_update_posted_date": "2013-03-18",
      "last_synced_at": "2026-11-19T07:17:24.281Z",
      "location_count": 5,
      "location_summary": "Boston, Massachusetts • Chapel Hill, North Carolina • Philadelphia, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00680342"
    },
    {
      "nct_id": "NCT04988386",
      "title": "Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Amyloid Cardiomyopathy, Transthyretin-Related"
      ],
      "interventions": [
        {
          "name": "Acoramidis (AG10)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eidos Therapeutics, a BridgeBio company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 389,
      "start_date": "2021-10-27",
      "completion_date": "2028-05-15",
      "has_results": false,
      "last_update_posted_date": "2025-10-14",
      "last_synced_at": "2026-11-19T07:17:24.281Z",
      "location_count": 26,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 21 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04988386"
    },
    {
      "nct_id": "NCT04629170",
      "title": "Safety and Tolerability of SYNB8802 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy",
        "Enteric Hyperoxaluria"
      ],
      "interventions": [
        {
          "name": "SYNB8802",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Synlogic",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 77,
      "start_date": "2020-11-04",
      "completion_date": "2023-01-17",
      "has_results": false,
      "last_update_posted_date": "2024-03-08",
      "last_synced_at": "2026-11-19T07:17:24.281Z",
      "location_count": 4,
      "location_summary": "Tucson, Arizona • Tampa, Florida • Knoxville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04629170"
    },
    {
      "nct_id": "NCT01262170",
      "title": "A Pilot Study to Evaluate Safety and Efficacy of CigRx™ in Smokers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Smoking",
        "Tobacco Use Disorder"
      ],
      "interventions": [
        {
          "name": "CigRx Lozenge",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Tobacco Lozenge",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "Rock Creek Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "23 Years",
        "maximum_age": "72 Years",
        "sex": "ALL",
        "summary": "23 Years to 72 Years"
      },
      "enrollment_count": 109,
      "start_date": "2010-04",
      "completion_date": "2010-04",
      "has_results": false,
      "last_update_posted_date": "2015-10-30",
      "last_synced_at": "2026-11-19T07:17:24.281Z",
      "location_count": 1,
      "location_summary": "Martinsburg, West Virginia",
      "locations": [
        {
          "city": "Martinsburg",
          "state": "West Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01262170"
    },
    {
      "nct_id": "NCT04469270",
      "title": "Study to Assess Safety and Efficacy of Engensis in Painful Diabetic Peripheral Neuropathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetic Neuropathy, Painful"
      ],
      "interventions": [
        {
          "name": "Engensis",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Helixmith Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 162,
      "start_date": "2020-11-20",
      "completion_date": "2024-07-31",
      "has_results": true,
      "last_update_posted_date": "2025-10-09",
      "last_synced_at": "2026-11-19T07:17:24.281Z",
      "location_count": 16,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 13 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04469270"
    },
    {
      "nct_id": "NCT05536973",
      "title": "Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neovascular Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "ADVM-022",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Adverum Biotechnologies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 69,
      "start_date": "2022-08-23",
      "completion_date": "2028-08",
      "has_results": false,
      "last_update_posted_date": "2026-10-27",
      "last_synced_at": "2026-11-19T07:17:24.281Z",
      "location_count": 34,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 30 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05536973"
    },
    {
      "nct_id": "NCT00644969",
      "title": "Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Smoking Cessation"
      ],
      "interventions": [
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "varenicline (CP-526,555)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 128,
      "start_date": "2008-05",
      "completion_date": "2010-04",
      "has_results": true,
      "last_update_posted_date": "2011-04-15",
      "last_synced_at": "2026-11-19T07:17:24.281Z",
      "location_count": 9,
      "location_summary": "Aurora, Colorado • Farmington, Connecticut • New Haven, Connecticut + 6 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Farmington",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00644969"
    },
    {
      "nct_id": "NCT06574269",
      "title": "A Study on TLC590 for Managing Postsurgical Pain",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Postsurgical Pain Management"
      ],
      "interventions": [
        {
          "name": "TLC590",
          "type": "DRUG"
        },
        {
          "name": "Ropivacaine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TLC Biopharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 120,
      "start_date": "2024-09-30",
      "completion_date": "2026-08",
      "has_results": false,
      "last_update_posted_date": "2025-12-02",
      "last_synced_at": "2026-11-19T07:17:24.281Z",
      "location_count": 2,
      "location_summary": "Bellaire, Texas • Houston, Texas",
      "locations": [
        {
          "city": "Bellaire",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06574269"
    },
    {
      "nct_id": "NCT03934541",
      "title": "Evaluating the Safety and Immunogenicity of an HIV-1 gp41 MPER-656 Liposome Vaccine in Healthy, HIV-uninfected Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "MPER-656 Liposome Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo for MPER-656 Liposome Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 24,
      "start_date": "2019-08-26",
      "completion_date": "2021-05-26",
      "has_results": true,
      "last_update_posted_date": "2025-09-25",
      "last_synced_at": "2026-11-19T07:17:24.281Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Boston, Massachusetts • New York, New York + 1 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03934541"
    }
  ]
}